Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter

 Grew global revenue 20% GAAP, 24% in constant currency

Received FDA authorization for Apollo ESGTM and Apollo REVISETM systems for treating patients with obesity

Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2022 and recent corporate highlights.

• Grew third quarter 2022 U.S. revenue by 29% and OUS revenue by 9% (18% in constant currency) over the same period in 2021;

• Grew third quarter 2022 Endoscopic Suturing System (ESS) revenue 41% (45% in constant currency) over the same period in 2021;

• Increased third quarter 2022 revenue from the Company's top 10 direct accounts by approximately 80% over the same period in 2021;

• Secured FDA marketing authorizations for Apollo ESGTM and Apollo REVISETM, new endoscopic systems for treatment of patients with obesity (BMI 30-50 kg/m2); and

• Announced publication of the landmark MERIT study for the Endoscopic Sleeve Gastroplasty procedure in The Lancet, demonstrating significant, durable weight loss results and an outstanding patient safety profile.

https://finance.yahoo.com/news/apollo-endosurgery-inc-reports-record-200100131.html